<DOC>
	<DOC>NCT02255656</DOC>
	<brief_summary>Primary Objective: To evaluate long-term safety of alemtuzumab. Secondary Objectives: To evaluate long term efficacy of alemtuzumab. To evaluate the safety profile of patients who received other Disease Modifying Treatment's (DMT) following alemtuzumab treatment. To evaluate patient-reported Quality of Life (QoL) outcomes and health resource utilization of patients who received alemtuzumab. To evaluate as needed re-treatment with alemtuzumab and other DMTs.</brief_summary>
	<brief_title>Phase IIIB-IV Long-Term Follow-up Study for Patients Who Participated in CAMMS03409</brief_title>
	<detailed_description>The total duration per patient is up to 5.5 years. As per Study Investigator discretion, patients can be treated with additional courses of alemtuzumab or any commercialized disease modifying treatment. All patients who complete CAMM03409 will be allowed into the study, which may include specific vulnerable populations. If the investigator decides to treat a patient with a course of alemtuzumab, appropriate cautionary measures will be applied as indicated in the approved labelling, or, in ex-EU countries where Lemtrada is not approved, according to the investigator's brochure.</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis, Relapsing-Remitting</mesh_term>
	<mesh_term>Alemtuzumab</mesh_term>
	<criteria>Inclusion criteria: Patient has completed at least 48 months of the Extension Study CAMMS03409. Signed written informed consent form. Exclusion criteria: Patient participating in another investigational interventional study. The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>